Want to see HK:3320 full AI Analyst Report?
China Resources Pharmaceutical Group Ltd. (3320) AI Stock Analysis
Top Page
China Resources Pharmaceutical Group Ltd.
(HKEX:3320)
The score is driven primarily by attractive valuation (low P/E and strong dividend yield). Financial performance is stable with solid cash flow, but very thin net margins and a rising leverage trend materially temper the outlook. Technicals are mildly supportive, adding a modest positive tilt.
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 29.12B
- Dividend Yield
- 5.17%
- Average Volume (3M)
- 8.13M
- Price to Earnings (P/E)
- 6.2
- Beta (1Y)
- 0.56
- Revenue Growth
- 7.94%
- EPS Growth
- 52.83%
- Country
- Hong Kong
- Employees
- 84,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments...
How the Company Makes Money
The company primarily makes money through (1) pharmaceutical distribution: selling medicines and healthcare products to hospitals, clinics, and other healthcare institutions, generating revenue based on the value and volume of products distributed an...
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Financial performance is steady: revenue growth resumed to mid-single digits in 2025 and operating profitability is consistent with modest improvement. However, net margins remain very thin (~1–1.5%), limiting earnings leverage, and balance-sheet leverage has increased materially (debt-to-equity ~1.83), raising financial risk despite solid cash generation.
Income Statement
63PositiveBalance Sheet
52NeutralCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 306.54B | 300.01B | 274.18B | 270.40B | 223.13B | 193.24B |
| Gross Profit | 50.14B | 49.53B | 43.30B | 42.43B | 34.36B | 28.87B |
| EBITDA | 17.97B | 18.55B | 16.36B | 15.34B | 13.59B | 9.79B |
| Net Income | 4.68B | 4.50B | 3.57B | 4.24B | 3.64B | 3.08B |
Balance Sheet | ||||||
| Total Assets | 340.15B | 318.34B | 274.28B | 271.48B | 214.19B | 202.83B |
| Cash, Cash Equivalents and Short-Term Investments | 44.03B | 31.05B | 27.28B | 35.46B | 28.56B | 30.45B |
| Total Debt | 114.17B | 104.87B | 73.43B | 62.16B | 56.06B | 55.45B |
| Total Liabilities | 202.24B | 187.52B | 169.90B | 169.20B | 134.14B | 125.57B |
| Stockholders Equity | 61.02B | 57.26B | 51.34B | 50.60B | 43.52B | 41.60B |
Cash Flow | ||||||
| Free Cash Flow | 18.01B | 18.83B | 14.55B | 12.42B | 6.62B | 6.79B |
| Operating Cash Flow | 20.97B | 22.78B | 17.55B | 15.55B | 9.57B | 9.16B |
| Investing Cash Flow | -7.29B | -11.20B | -9.45B | -2.07B | -2.90B | -7.21B |
| Financing Cash Flow | -15.98B | -12.19B | -17.91B | -4.07B | -7.90B | 4.34B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3320, the sentiment is Positive. The current price of 4.63 is above the 20-day moving average (MA) of 4.49, above the 50-day MA of 4.43, and above the 200-day MA of 4.61, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 58.15 is Neutral, neither overbought nor oversold. The STOCH value of 47.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3320.
China Resources Pharmaceutical Group Ltd. Peers Comparison
Overall Rating
HK:151377Outperform- HK:332068Neutral
HK:086761Neutral
HK:087457Neutral
HK:219657Neutral
HK:393354Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1513 | 77Outperform | HKD 26.72B | 16.30 | 11.32% | 6.71% | -9.56% | -23.22% |
| HK:3320 | 68Neutral | HKD 29.12B | 6.18 | 7.92% | 5.17% | 7.94% | 52.83% |
| HK:0867 | 61Neutral | HKD 23.94B | 13.43 | 8.60% | 3.50% | 14.80% | -2.88% |
| HK:0874 | 57Neutral | HKD 35.32B | 14.74 | 5.57% | 6.71% | 6.00% | -23.05% |
| HK:2196 | 57Neutral | HKD 65.63B | 17.04 | 7.14% | 2.73% | 9.88% | 9.30% |
| HK:3933 | 54Neutral | HKD 13.46B | 20.80 | 3.12% | 4.38% | -12.86% | -83.10% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:3320 | China Resources Pharmaceutical Group Ltd. | 4.63 | -0.11 | -2.26% | |
| HK:3933 | The United Laboratories International | 6.83 | -5.69 | -45.46% | |
| HK:0867 | China Medical System Holdings | 9.81 | -3.65 | -27.10% | |
| HK:0874 | Guangzhou Baiyunshan Pharmaceutical Holdings Company Class H | 12.86 | -5.10 | -28.41% | |
| HK:1513 | Livzon Pharmaceutical Group Class H | 23.18 | -5.02 | -17.81% | |
| HK:2196 | Shanghai Fosun Pharmaceutical (Group) Co Class H | 16.47 | -6.58 | -28.55% |
China Resources Pharmaceutical Group Ltd. Corporate Events
China Resources Pharmaceutical Moves to Become Largest Shareholder in Lier Chemical
China Resources Pharmaceutical Group Ltd., a Hong Kong-listed player in the pharmaceutical and healthcare products sector, is expanding its reach through its subsidiary CR Double-Crane. The subsidiary acts as a strategic investment arm, targeting equ...
China Resources Pharmaceutical Raises RMB1 Billion in Second Tranche of 2026 Medium-Term Notes
China Resources Pharmaceutical Group Limited has announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the issuance of the second tranche of its 2026 medium-term notes in mainland China. Th...
China Resources Pharmaceutical Raises RMB1 Billion via Medium-Term Notes in Mainland China
China Resources Pharmaceutical Group has completed the issuance of the first tranche of its 2026 medium term notes in the mainland China market via its wholly-owned unit China Resources Pharmaceutical Holdings. The notes carry a principal amount of R...
China Resources Pharma Leads Bid for Strategic Stake in Lier Chemical
China Resources Pharmaceutical Group has disclosed that its indirect subsidiary China Resources Double-Crane Pharmaceutical ranked first in a public bidding process to acquire a 23.50% stake in Lier Chemical, a Shenzhen-listed producer of high-effici...
Tasly Delivers Profit Growth on Flat Revenue, Bolstering China Resources Pharmaceutical
China Resources Pharmaceutical Group has disclosed key unaudited interim figures from its subsidiary Tasly Pharmaceutical for the six months to 30 June 2026, highlighting the performance of one of its core assets in the mainland market. Tasly, listed...
CR Sanjiu’s First-Half 2026 Profit Declines Despite Revenue Growth
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., a key subsidiary of China Resources Pharmaceutical Group Limited, reported unaudited preliminary financial results for the six months ended 30 June 2026. The Shenzhen-listed pharmaceutica...
China Resources’ KPC Warns of Steep First‑Half Loss Amid Policy and Market Pressures
KPC Pharmaceuticals, a Shanghai‑listed subsidiary of China Resources Pharmaceutical Group, reported a sharp deterioration in earnings for the six months to 30 June 2026, with an unaudited net loss of RMB330 million to RMB400 million expected. E...
China Resources Pharmaceutical Refreshes Board With New Non-Executive Director
China Resources Pharmaceutical Group Ltd., a Hong Kong-incorporated and Hong Kong-listed pharmaceutical enterprise, runs extensive operations across China’s healthcare sector, from drug manufacturing to distribution and related medical services...
China Resources Pharmaceutical Details Board and Committee Structure
China Resources Pharmaceutical Group Limited has disclosed the current composition of its board of directors, detailing the roles of its chairman, president, executive, non-executive, and independent non-executive directors. The announcement also out...
China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group, has completed the public issuance of the third tranche of its 2026 corporate bonds in mainland China. Th...
China Resources Pharmaceutical Wins Shareholder Backing for Dividend, Board and Capital Mandates
China Resources Pharmaceutical Group’s shareholders approved all resolutions at the 12 June 2026 annual general meeting, including adoption of the 2025 financial statements and a final dividend of RMB0.122 per share. Investors also backed the r...
China Resources Pharmaceutical Wins Approval to Register Up to RMB5 Billion in Medium-Term Notes
China Resources Pharmaceutical Group said its wholly owned unit, China Resources Pharmaceutical Holdings, has obtained registration approval from China’s National Association of Financial Market Institutional Investors to issue up to RMB5 billi...
China Resources Pharmaceutical Sets Final 2025 Dividend Timetable
China Resources Pharmaceutical Group Limited has declared a final ordinary dividend of RMB 0.122 per share for the financial year ended 31 December 2025, with shareholders able to receive it in either Hong Kong dollars or renminbi. The default paymen...
China Resources Pharmaceutical Sets AGM to Approve Dividend, Board Mandates and Share Buy-Back
China Resources Pharmaceutical Group Ltd. has called its annual general meeting for 12 June 2026 in Hong Kong to review the audited financial statements for the year ended 31 December 2025 and to seek shareholder approval for key corporate matters. T...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026